Priska Kaufmann

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Topics

Direct Oral Anticoagulants

Coronary Artery

Top Venues

Journal of clinical pharmacology

British journal of clinical pharmacology

Pharmacology research & perspectives

This page only lists publications with an associated author ORCID identifier.

Publications

Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D (2024)
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D 24 (1) (2024)
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D 24 (1) (2024)
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D 24 (1) (2024)
Massimo Magliocca, Benjamin Berger, Vincent Lemoine, Priska Kaufmann, Jasper Dingemanse
Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A. Journal of clinical pharmacology (2024)
Massimo Magliocca, Benjamin Berger, Vincent Lemoine, Priska Kaufmann, Jasper Dingemanse
Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A. Journal of clinical pharmacology 64 (9) (2024)
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Géhin, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D 24 (1) (2024)
Marion Anliker-Ort, Jasper Dingemanse, Luboš Janů, Priska Kaufmann
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects. Clinical drug investigation (2023)
Benjamin Berger, Priska Kaufmann, Matthias Berse, Alexander Treiber, Nathalie Grignaschi, Jasper Dingemanse
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects. Pharmacology research & perspectives 11 (5) (2023)
Marion Anliker-Ort, Chih-Hsuan Hsin, Andreas Krause, Marc Pfister, John van den Anker, Jasper Dingemanse, Priska Kaufmann
Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist. Pharmacology research & perspectives 11 (4) (2023)
Marion Anliker-Ort, Jasper Dingemanse, Chih-Hsuan Hsin, Muriel Richard, Eva Huehn, Giancarlo Sabattini, Jeroen van de Wetering, Rüdiger Kornberger, John van den Anker, Priska Kaufmann
First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients. Basic & clinical pharmacology & toxicology 131 (2) (2022)
Marion Anliker-Ort, Jasper Dingemanse, Hervé Farine, Peter M A Groenen, Rüdiger Kornberger, John van den Anker, Priska Kaufmann
Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist: Tolerability, pharmacokinetics and target engagement. British journal of clinical pharmacology (2022)
Muriel Richard, Priska Kaufmann, Marion Anliker-Ort, Rüdiger Kornberger, Jasper Dingemanse
Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug. CNS drugs 34 (3) (2021)
Priska Kaufmann, Marion Ort, Georg Golor, Rüdiger Kornberger, Jasper Dingemanse
First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist. British journal of clinical pharmacology 86 (7) (2020)
Benjamin Berger, Priska Kaufmann, Annelize Koch, Jasper Dingemanse
Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects. Journal of clinical pharmacology 60 (7) (2020)